Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
| Autor: | Joaquin Martinez-Lopez, Laida Cuevas Palomares, Pilar Rodríguez Martínez, María Belén Vidriales Vicente, Susana Vives, Raimundo Garcia Boyero, Isabel Cano, Lourdes Hermosín Ramos, María Carmen Mateos Rodríguez, Cristian Escolano Escobar, María Telesa Olave, Cristina Seri Merino, Montserrat Arnan Sangerman, Juan Miguel Bergua Burgues, Marta Cervera Calvo, María Elena Amutio Diez, Javier Cornago Navascués, Jose Luis Lopez Lorenzo, Miguel A. Sanz, Carmen Botella Prieto, José Luis Piñana, Josefina Serrano, Almudena de Laiglesiai, Jesús Lorenzo Algarra, Alejandro Contento Gonzalo, Pau Montesinos, Carlos Cerveró, Pilar Herrera, Rebeca Cuello García, Gabriela Rodriguez Macias, Marta Sobas, Angela Figuera Alvarez, Begona Navas Elorza, María Josefa Najera Irazu, Maria Angeles Foncillas, Dunia De Miguel Llorente, Erik de Cabo López, Alicia Roldán Pérez, Teresa Bernal del Castillo, Juan Eduardo Megías-Vericat, Paola Sandra Villafuerte Gutierrez, Villegas A, Tomás Palanques-Pastor |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty viruses acute myeloid leukemia COVID-19 SARS-CoV-2 acute myeloid leukemia hematological malignancies Intensive care Internal medicine hemic and lymphatic diseases medicine hematological malignancies skin and connective tissue diseases business.industry SARS-CoV-2 Mortality rate Myeloid leukemia COVID-19 virus diseases Lopinavir Adult Acute Myeloid Leukemia Hematology medicine.disease body regions Leukemia Oncology Absolute neutrophil count Ritonavir business medicine.drug |
| Zdroj: | Leukemia & lymphoma r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname LEUKEMIA & LYMPHOMA r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| ISSN: | 1042-8194 |
| Popis: | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|